Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression.
暂无分享,去创建一个
[1] A. Schmaier,et al. Identification of prolylcarboxypeptidase as the cell matrix‐associated prekallikrein activator , 2002, FEBS letters.
[2] A. Schmaier,et al. Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator* , 2002, The Journal of Biological Chemistry.
[3] A. Schmaier. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. , 2002, The Journal of clinical investigation.
[4] A. Schmaier,et al. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. , 2001, Blood.
[5] A. Schmaier,et al. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. , 2001, American journal of physiology. Heart and circulatory physiology.
[6] D. Shaw,et al. Two‐chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5 , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] P. J. Anderson,et al. Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease. , 2000, Genomics.
[8] R. Colman,et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. , 2000, Blood.
[9] T. Renné,et al. Mapping of the Discontinuous H-kininogen Binding Site of Plasma Prekallikrein , 1999, The Journal of Biological Chemistry.
[10] V. Nicaud,et al. Venous Thromboembolic Disease and the Prothrombin, Methylene Tetrahydrofolate Reductase and Factor V Genes , 1999, Thrombosis and Haemostasis.
[11] A. Schmaier,et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. , 1998, Blood.
[12] R. Colman,et al. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. , 1997, Blood.
[13] A. Schmaier,et al. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. , 1996, Circulation.
[14] T. Renné,et al. Mapping of the Discontinuous Kininogen Binding Site of Prekallikrein , 1996, The Journal of Biological Chemistry.
[15] A. Schmaier,et al. Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5 (*) , 1995, The Journal of Biological Chemistry.
[16] R. Colman,et al. Genetic basis of total kininogen deficiency in Williams' trait. , 1993, The Journal of biological chemistry.
[17] M. Haasemann,et al. Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties. , 1993, The Journal of biological chemistry.
[18] A. Schmaier,et al. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. , 1992, Blood.
[19] A. Schmaier,et al. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. , 1992, The Journal of biological chemistry.
[20] A. Schmaier,et al. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. , 1991, The Journal of biological chemistry.
[21] J. Kellermann,et al. Mapping of the prekallikrein-binding site of human H-kininogen by ligand screening of lambda gt11 expression libraries. Mimicking of the predicted binding site by anti-idiotypic antibodies. , 1990, The Journal of biological chemistry.
[22] A. Kakizuka,et al. A set of U1 snRNA-complementary sequences involved in governing alternative RNA splicing of the kininogen genes. , 1990, The Journal of biological chemistry.
[23] T. Tsuda,et al. Molecular genetic survey of five Japanese families with high-molecular-weight kininogen deficiency. , 1990, Blood.
[24] R. Schein,et al. Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. , 1988, The Journal of laboratory and clinical medicine.
[25] N. Kitamura,et al. Localization of DNA sequences governing alternative mRNA production of rat kininogen genes. , 1988, The Journal of biological chemistry.
[26] K. Fujikawa,et al. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. , 1987, The Journal of biological chemistry.
[27] R. Colman,et al. Evaluation of a microassay for human plasma prekallikrein. , 1987, The Journal of laboratory and clinical medicine.
[28] A. Schmaier,et al. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. , 1987, The Journal of biological chemistry.
[29] A. Barrett,et al. Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. , 1986, The Biochemical journal.
[30] A. Schmaier,et al. High-molecular weight kininogen. A secreted platelet protein. , 1983, The Journal of clinical investigation.
[31] O. Carretero,et al. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. , 1982, The Journal of laboratory and clinical medicine.
[32] R. Colman,et al. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. , 1980, The Journal of clinical investigation.
[33] E. G. Erdös,et al. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. , 1978, The Journal of biological chemistry.
[34] R. Colman,et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. , 1975, The Journal of clinical investigation.
[35] R. Waldmann,et al. FITZGERALD FACTOR: A HITHERTO UNRECOGNISED COAGULATION FACTOR , 1975, The Lancet.